Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "SIFI"

338 News Found

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
News | December 07, 2024

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator


Granules India update on USFDA inspection at Gagillapur facility
News | December 05, 2024

Granules India update on USFDA inspection at Gagillapur facility

Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA


Aster DM Healthcare to acquire the balance stake in Aster Aadhar Hospital
Healthcare | November 28, 2024

Aster DM Healthcare to acquire the balance stake in Aster Aadhar Hospital

The 254-bedded Aster Aadhar Hospital, Kolhapur is the city's most comprehensive multi-speciality hospital


Univar Solutions becomes exclusive distributor of SD Head USA Pharmaceutical excipients in North America
Supply Chain | November 16, 2024

Univar Solutions becomes exclusive distributor of SD Head USA Pharmaceutical excipients in North America

Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions


Hikal Q2 FY25 revenue stood at Rs. 453 Cr
News | November 13, 2024

Hikal Q2 FY25 revenue stood at Rs. 453 Cr

In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%


Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr
News | November 11, 2024

Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr

Growth markets revenue increased by 44 YoY to Rs. 812 crore


Granules India’s Unit V facility secures USFDA EIR with NAI status
Drug Approval | November 10, 2024

Granules India’s Unit V facility secures USFDA EIR with NAI status

The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit


Briefs: Sun Pharmaceutical Industries and Biocon Biologics
News | November 04, 2024

Briefs: Sun Pharmaceutical Industries and Biocon Biologics

The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI


Indoco Remedies receives OAI status from USFDA for Goa plant 2 & 3
Drug Approval | October 14, 2024

Indoco Remedies receives OAI status from USFDA for Goa plant 2 & 3

Indoco is comprehensively working on the remedial action plan


Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility
News | October 04, 2024

Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility

US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years